Article ; Online: B-cell engineering: A promising approach towards vaccine development for COVID-19.
2020 Volume 144, Page(s) 109948
Abstract: ... COVID-19). It can be argued that a vaccine may be the most efficient way to contain the spread ... genome editing approach can be repurposed into a cell-modification endeavor in addition to (and rather ... antibody producing cells which may serve as an effective vaccine for SARS-CoV-2 and, by the same rationale, other viruses ...
| Abstract | With the number of cases crossing six million (and more than three hundred and seventy thousand deaths) worldwide, there is a dire need of a vaccine (and repurposing of drugs) for SARS-CoV-2 disease (COVID-19). It can be argued that a vaccine may be the most efficient way to contain the spread of this disease and prevent its future onset. While many attempts are being made to design and develop a vaccine for SARS-CoV-2, pertinent technological hitches do exist. That is perhaps one of the reasons that we don't have vaccine for coronaviruses (including SARS-CoV-1 and MERS). Recently developed CRISPR-mediated genome editing approach can be repurposed into a cell-modification endeavor in addition to (and rather than) correcting defective parts of genome. With this premise, B-cells can be engineered into universal donor, antigen specific, perpetually viable, long lasting, non-oncogenic, relatively benign, antibody producing cells which may serve as an effective vaccine for SARS-CoV-2 and, by the same rationale, other viruses and pathogens. |
|---|---|
| MeSH term(s) | Animals ; Antibodies, Viral/biosynthesis ; Antibodies, Viral/genetics ; B-Lymphocytes/immunology ; B-Lymphocytes/virology ; COVID-19/immunology ; COVID-19/prevention & control ; COVID-19/virology ; COVID-19 Vaccines/biosynthesis ; COVID-19 Vaccines/genetics ; Cell Engineering/methods ; Genetic Engineering/methods ; Host Microbial Interactions/genetics ; Host Microbial Interactions/immunology ; Humans ; Mice ; Models, Genetic ; Models, Immunological ; Pandemics/prevention & control ; SARS-CoV-2/genetics ; SARS-CoV-2/immunology |
| Chemical Substances | Antibodies, Viral ; COVID-19 Vaccines |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-06-02 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 193145-3 |
| ISSN | 1532-2777 ; 0306-9877 |
| ISSN (online) | 1532-2777 |
| ISSN | 0306-9877 |
| DOI | 10.1016/j.mehy.2020.109948 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1132: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.